Barely Significant
← all excerpts

Interleukin-1 Receptor Antagonist as Therapy for Traumatic Brain Injury.

Neurotherapeutics · 2023 · PMC10684479 · PMID 37610701

1
hedged sentence
closest p
boldest claim

The sentences

The discrepancy between the results of these two systematic reviews is likely a consequence of broader inclusion criteria as Zeiler and colleagues included pediatric studies [ 117 , 118 ], one study that demonstrated a borderline significant trend between CSF-IL-1β and outcome [ 119 ], as well as one study predominantly describing increased CSF levels of IL-1β without a clear relationship to outcome [ 120 ].

also in 64 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.